JP2022513363A5 - - Google Patents

Info

Publication number
JP2022513363A5
JP2022513363A5 JP2021546056A JP2021546056A JP2022513363A5 JP 2022513363 A5 JP2022513363 A5 JP 2022513363A5 JP 2021546056 A JP2021546056 A JP 2021546056A JP 2021546056 A JP2021546056 A JP 2021546056A JP 2022513363 A5 JP2022513363 A5 JP 2022513363A5
Authority
JP
Japan
Prior art keywords
glp1
fusion protein
pharmaceutical composition
gdf15 fusion
gdf15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513363A (ja
JP7539902B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059029 external-priority patent/WO2020084496A1/en
Publication of JP2022513363A publication Critical patent/JP2022513363A/ja
Publication of JP2022513363A5 publication Critical patent/JP2022513363A5/ja
Priority to JP2024135217A priority Critical patent/JP2024170428A/ja
Application granted granted Critical
Publication of JP7539902B2 publication Critical patent/JP7539902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546056A 2018-10-22 2019-10-22 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用 Active JP7539902B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135217A JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22
US62/748,603 2018-10-22
PCT/IB2019/059029 WO2020084496A1 (en) 2018-10-22 2019-10-22 Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135217A Division JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022513363A JP2022513363A (ja) 2022-02-07
JP2022513363A5 true JP2022513363A5 (https=) 2022-10-27
JP7539902B2 JP7539902B2 (ja) 2024-08-26

Family

ID=70330680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546056A Active JP7539902B2 (ja) 2018-10-22 2019-10-22 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Country Status (24)

Country Link
US (3) US11713345B2 (https=)
EP (2) EP4520343A3 (https=)
JP (2) JP7539902B2 (https=)
KR (1) KR20210081389A (https=)
CN (2) CN119751697A (https=)
AU (2) AU2019368816B2 (https=)
BR (1) BR112021007376A2 (https=)
CA (1) CA3116983A1 (https=)
CL (1) CL2021000987A1 (https=)
CO (1) CO2021005051A2 (https=)
CR (1) CR20210193A (https=)
DO (1) DOP2021000075A (https=)
EA (1) EA202191105A1 (https=)
EC (1) ECSP21028914A (https=)
ES (1) ES3011982T3 (https=)
IL (1) IL282297B1 (https=)
JO (1) JOP20210084A1 (https=)
MX (1) MX2021004665A (https=)
MY (1) MY205905A (https=)
PE (1) PE20211078A1 (https=)
PH (1) PH12021550885A1 (https=)
SA (1) SA521421825B1 (https=)
SG (1) SG11202103990QA (https=)
WO (1) WO2020084496A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP3883960A4 (en) * 2018-11-20 2022-11-09 Janssen Pharmaceutica NV GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE
WO2020185533A1 (en) * 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
CN117750968A (zh) * 2021-05-21 2024-03-22 株式会社柳韩洋行 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN120530128A (zh) * 2022-11-18 2025-08-22 株式会社柳韩洋行 双功能蛋白及其用途
CN116813742A (zh) * 2022-11-22 2023-09-29 杭州博茵生物技术有限公司 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
WO2024144431A1 (ru) * 2022-12-29 2024-07-04 Авва Фармасьютикалс Лтд Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌを標的にするアンチセンスオリゴマー及びこの用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
WO2008011446A2 (en) * 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
WO2009142773A2 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
US9012719B2 (en) * 2009-02-06 2015-04-21 Syngenta Participations Ag Modification of multidomain enzyme for expression in plants
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
KR20120097481A (ko) 2009-07-20 2012-09-04 내셔날 쳉쿵 유니버시티 사람 혈청 알부민(ＨＳＡ)의 변이체와 컨쥬게이션된 αｖβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도
WO2012091564A2 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
LT2948559T (lt) 2013-01-25 2018-06-25 Janssen Biotech, Inc. Kv1.3 antagonistai ir jų panaudojimo būdai
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6475233B2 (ja) 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
KR20190059312A (ko) 2016-10-12 2019-05-30 얀센 바이오테크 인코포레이티드 Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP3883960A4 (en) 2018-11-20 2022-11-09 Janssen Pharmaceutica NV GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE

Similar Documents

Publication Publication Date Title
JP2022513363A5 (https=)
US8889619B2 (en) Fusion protein of Exendin-4 and its analog, preparation method and use thereof
JP7268202B2 (ja) 代謝性疾患を治療するための融合タンパク質
US8304386B2 (en) Long-acting growth hormone and methods of producing same
US20210070829A1 (en) Multi-domain active protein for treating metabolic diseases
US10538586B2 (en) Compositions and methods for treating fatty tissue buildup
JP2021184727A (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
CN114621339B (zh) 一种长效glp-1衍生物
CN102770538A (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
AU2020233876B2 (en) Growth differentiation factor 15 combination therapy
JP7058670B2 (ja) 増殖分化因子１５融合タンパク質
US20150361154A1 (en) Therapeutic agents, compositions, and methods for glycemic control
TW201414750A (zh) 用於治療代謝症狀的融合蛋白
JP2010031018A5 (https=)
US20250223331A1 (en) Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof
CN106432509B (zh) 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
NZ794312A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
US10736970B2 (en) Polypeptide complex of titin-telethonin beta-pleated sheet structure as polypeptide drug carrier, method of using the polypeptide complex, and fusion protein complex thereof
JP2022518850A (ja) 線維芽細胞成長因子２１変異体、その融合タンパク質とその使用
CN114891090B (zh) 一种酰化的长效glp-1衍生物
US12508299B2 (en) Compositions and methods for treating obesity and hyperphagia
MX2012005912A (es) Conjugado de polipeptido.
US20240424072A1 (en) Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor
WO2022143516A1 (zh) 一种人glp-1多肽变体及其应用
WO2021083306A1 (zh) Glp-1/gcg双受体激动剂多肽